Acura Pharmaceuticals to Develop Abuse Deterrent Hydrocodone With Acetaminophen Tablets With Limitx(TM) Technology - Seite 2

Phase I Research on the Company's hydromorphone tablet utilizing LIMITX technology is supported by the National Institute on Drug Abuse of the National Institutes of Health under Award Number R44DA037921. The results and content of any such research is solely the responsibility of Acura and does not necessarily represent the official views of the National Institutes of Health.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION^® and IMPEDE^® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

In June 2011, the U.S. Food and Drug Administration approved OXAYDO™ (oxycodone HCl immediate-release tablets) which incorporates the AVERSION Technology. On January 7, 2015, we entered into a Collaboration and License Agreement with Egalet US, Inc. and Egalet Ltd., each a subsidiary of Egalet Corporation, pursuant to which we exclusively licensed to Egalet worldwide rights to manufacture and commercialize OXAYDO.

Acura also markets NEXAFED^® and NEXAFED^® Sinus, which are pseudoephedrine containing products that utilize the IMPEDE technology.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forwarding-looking statements may include, but are not limited to, the results of our clinical development of our hydrocodone/APAP product using our LIMITX technology, whether our hydrocodone/APAP formulation will lead to a commercial product, whether or when we are able to obtain FDA approval of this product candidate, whether we will be able to promote the abuse-deterrent features of our LIMITX technology, whether our product candidates utilizing our LIMITX technology will actually deter excess oral consumption or nasal snorting, and whether competitors will develop and commercialize products using alternative abuse-deterrent technologies that are more effective than our LIMITX technology. Such forwarding-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail in our filings with the Securities and Exchange Commission. Unless required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments.